PP2A Promotes the Symmetric Division of MUC1‐Dominant Cancer Stem‐Like Cells in Small Cell Lung Cancer
Advanced Science · 2025
DOI: 10.1002/advs.202503545 ↗At a glance
Journal article in Advanced Science, 2025. Written by Shengze Li and 15 co-authors. Institution: Department of Histoembryology, Genetics and Developmental Biology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Educat…. Major MEDLINE topics: Protein Phosphatase 2, Mucin-1, Small Cell Lung Carcinoma, Lung Neoplasms. Cited 3 times so far (Crossref); 85 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China.
Abstract (original language)
Small cell lung cancer (SCLC) is the most aggressive and lethal subtype of lung cancer. Cancer stem‐like cells (CSLCs) are primarily responsible for carcinogenesis, therapeutic resistance, and tumor recurrence. This study reported that high level of mucin1 (MUC1) is associated with poor patient survival in SCLC. MUC1 expression peaks during the G2/M phase and facilitates symmetric division and expansion of CSLCs. Mechanistically, the interaction of MUC1 and protein phosphatase 2A (PP2A) results in augmented PP2A activity, which leads to reduced phosphorylation of protein kinase C ζ (PKCζ), ultimately decreases phosphorylation of NUMB. Both pharmacological and genetic strategies demonstrate that targeted‐inhibition of the MUC1‐PP2A axis pointedly rescues phosphorylation of PKCζ and NUMB, thereby shifting CSLCs towards asymmetric division and represses CSLCs proliferation. Conversely, inhibitor of PKCζ suppresses phosphorylation of NUMB, promotes symmetric division and induces enrichment of CSLCs. Moreover, combination of etoposide and inhibitors of MUC1‐PP2A pathway efficiently constrains tumor growth in vitro and in vivo. Importantly, a negative correlation is observed between MUC1 and phosphorylation of PKCζ and NUMB in SCLC patients. Therefore, this study reveals a novel mechanism by which MUC1‐PP2A awakes CSLC expansion via switching symmetric division, suggesting a potential therapeutic strategy for MUC1‐positive SCLC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Histoembryology, Genetics and Developmental Biology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Key Laboratory of Reproductive Medicine, Shanghai Jiao T…
- Center for Molecular Medicine, Children's Hospital of Fudan University, Shanghai, 201102, China.
- Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, China.
- Department of Respiratory Medicine, Xiangya Hospital, Central South University, Hunan, 410028, China.
- Department of Laboratory Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 201112, China.
ORCID profiles: Shengze Li, Lei Huang
Funding
- National Natural Science Foundation of China
Cite
APA
Li, S., Dong, X., Gao, K., Wang, Y., Li, M., Deng, H., Ma, S., Lv, Y., Jin, W., Li, Q., Wang, Y., Liao, X., Bian, K., Zhou, A., Hu, C., & Huang, L. (2025). PP2A Promotes the Symmetric Division of MUC1‐Dominant Cancer Stem‐Like Cells in Small Cell Lung Cancer. Advanced Science. https://doi.org/10.1002/advs.202503545
Vancouver
Li S, Dong X, Gao K, Wang Y, Li M, Deng H, et al. PP2A Promotes the Symmetric Division of MUC1‐Dominant Cancer Stem‐Like Cells in Small Cell Lung Cancer. Advanced Science. 2025. doi:10.1002/advs.202503545
BibTeX
@article{Li2025,
author = {Li, Shengze and Dong, Xinran and Gao, Kexing and Wang, Yiyang and Li, Min and Deng, Huayun and Ma, Shuangyu and Lv, Yaping and Jin, Wei and Li, Quanfu and Wang, Yuming and Liao, Xiaodong and Bian, Kangjing and Zhou, Aiwu and Hu, Chengping and Huang, Lei},
title = {PP2A Promotes the Symmetric Division of MUC1‐Dominant Cancer Stem‐Like Cells in Small Cell Lung Cancer},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202503545}
}
EUVIMED